ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 213

Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease

Annette de Thurah1,2, Ina Trolle Andersen3, Andreas Bugge Tingaard4, Josephine Therkildsen5, Anders Hammerich Riis3, Morten Böttcher5 and Ellen-Margrethe Hauge6,7, 1Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, 2Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 4Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, 5Cardiology, Regional Hospital of Herning, Herning, Denmark, 6Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 7Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Disease Activity, registry and rheumatoid arthritis (RA), Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after initial diagnosis and treatment for coronary artery disease (CAD) is unknown.

Objective:

To examine the risk of major cardiovascular events (MACE) and all-cause mortality among RA and non-RA patients after referral to cardiac computed tomography (CCT) due to symptoms suggestive of CAD.

Methods:

This was a follow-up study, using data from the Western Denmark Heart Registry [1] covering all diagnostic procedures in a catchment area with approximately 3.3 mill. inhabitants. The register provides information on clinical variables such as smoking, severity of stenosis and calcium score. Information on RA diagnosis and co-variates were identified through individual-level linkage of nationwide administrative registers.

Outcome measures were MACE alone and a combined outcome (CO) including MACE, coronary artery bypass grafting, percutaneus coronary intervention, and all-cause mortality. Median time until events or censoring were 3.5 years (min/max: 0.0: 9.2).

In the studied region, RA-flares are controlled through escalation of disease modifying drugs and intra-articular or intramuscular glucocorticoid injections (GCI). Hence, the number of times a patient had received GCIs 3 years prior to the CCT were used as a surrogate marker of disease activity. Analyses were performed for overall RA and the serological subtypes: ‘seropositive RA’(ICD-10: M05) and ‘other RA’(ICD-10: M06).

Cox proportional hazard models were used to examine the association between RA and non-RA patients and the outcomes.

Results:

We included 42,257 patients, and identified 358 (0.8%) patients with RA. The incidence rate for revascularization, not related to the initial diagnosis, in RA and non-RA patients was 3.4 (95% CI 1.3-9.0) vs. 3.7 (95%CI 3.7-4.1)/1000 person-years. For both the CO and MACE an increased risk was seen in RA compared to non-RA (CO: hazard ratio (HR): 1.35 (95% CI: 0.93-1.96), MACE: HR 1.94 (95% CI: 1.18-3.19)). The risk was higher among patients who had received GCI more than one time during 3 years prior to the CT (CO:  HR: 1.80 (95% CI: 1.1-3.0), MACE: HR 3.02 (95% CI: 1.62-5.65)) and in patients with sero-positive RA (CO: HR: 1.42 (95% CI: 0.93-2.16), MACE: HR: 2.45 (95% CI: 1.47-4.08)) (Fig. 1). 

Conclusion:

We found a strong association between RA and cardiovascular events in the period after the initial diagnosis and treatment in this cohort of patients with a-priori risk of CAD referred for cardiac CT . These findings support that RA per se, but in particular, sero-positivity and inflammation related to flares increase the risk of CVD and mortality.

1. Nielsen LH, Bottcher M, et al. The Western Denmark Cardiac Computed Tomography Registry: a review and validation study. Clinical epidemiology 2014.

 



Disclosure: A. de Thurah, None; I. Trolle Andersen, None; A. Bugge Tingaard, None; J. Therkildsen, None; A. Hammerich Riis, None; M. Böttcher, None; E. M. Hauge, None.

To cite this abstract in AMA style:

de Thurah A, Trolle Andersen I, Bugge Tingaard A, Therkildsen J, Hammerich Riis A, Böttcher M, Hauge EM. Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/excessive-risk-of-major-cardiovascular-events-in-sero-positive-rheumatoid-arthritis-and-in-patients-with-active-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/excessive-risk-of-major-cardiovascular-events-in-sero-positive-rheumatoid-arthritis-and-in-patients-with-active-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology